02/21/2021 7:25 PM
Clarín.com
Society
Updated 02/21/2021 7:25 PM
One million doses of the coronavirus vaccine developed by the Chinese laboratory Sinopharm will arrive on Thursday from Beijing, according to the Telam agency on Sunday.
The million doses of Sinopharm will immunize 500,000 people, since this drug, like most vaccines against Covid-19, requires two applications.
The new Minister of Health, Carla Vizzotti, confirmed this Sunday in radio statements that the approval for the emergency use of Sinopharm from China is "in the last instance", since the ANMAT received "the information of the phase 3 trial, interim analysis, as for all vaccines ".
In addition, the official explained that the control body "made specific inquiries and they have been answered", a process that in the case of Sinopharm was favored because the Chinese state laboratory carried out phase 3 studies simultaneously in various parts of the world (United Arab Emirates States, Egypt, Bahrain, Serbia, Peru, Pakistan, Morocco) but also in Argentina.
Indeed, in the country the trials were carried out on a control population of 3,008 volunteers who participated in a "randomized study" (they receive a random vaccine or placebo) from the association of the Chinese pharmaceutical group with the Vacunar network and the Host Foundation plus the ELEA laboratory (from Grupo Insud) as a local sponsor.
The person in charge of the Sinopharm trials in Argentina was the infectious disease specialist Pedro Cahn, founder of the Fundación Huiuda.
"It is extremely safe, in the trials we have not registered serious adverse events related to the vaccine, so from the point of view of safety I can give you a guarantee," Cahn said before the Télam consultation, adding: "From the point of view of safety In terms of efficacy, they (because of the laboratory that produces it) have reported efficacy similar to that of other vaccines. "
"It is good news that these vaccines are arriving, because they will allow us to expand the menu of offers and accelerate the vaccination process," Cahn completed.
On the other hand, and beyond the immediate, the arrival of this million doses of Sinopharm could be the first batch of a series of new purchases, sources that follow the negotiation in detail assured Telam.
In fact, the pharmaceutical group that developed the drug, China National Pharmaceutical Group, has already warned that from March it will be ready to periodically supply significant quantities, well over a million.
With data from Télam
DD